Tandem Diabetes Care Inc TNDM
We take great care to ensure that the data presented and summarized in this overview for TANDEM DIABETES CARE INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TNDM
View all-
Black Rock Inc. New York, NY9.23MShares$478 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.05MShares$365 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA3.67MShares$190 Million0.02% of portfolio
-
Marshall Wace, LLP London, X03.12MShares$161 Million0.17% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO2.93MShares$152 Million1.29% of portfolio
-
Jennison Associates LLC2.56MShares$132 Million0.06% of portfolio
-
State Street Corp Boston, MA2.24MShares$116 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.2MShares$114 Million0.04% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.03MShares$105 Million1.13% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.51MShares$78.3 Million0.32% of portfolio
Latest Institutional Activity in TNDM
Top Purchases
Top Sells
About TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Insider Transactions at TNDM
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 28
2024
|
John F Sheridan PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
416
-0.9%
|
$21,216
$51.73 P/Share
|
May 28
2024
|
John F Sheridan PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
820
+1.75%
|
-
|
May 28
2024
|
James Leal Chief Manufacturing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
129
-0.76%
|
$6,579
$51.73 P/Share
|
May 28
2024
|
James Leal Chief Manufacturing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
310
+1.79%
|
-
|
May 28
2024
|
Leigh Vosseller EVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
145
-0.76%
|
$7,395
$51.73 P/Share
|
May 28
2024
|
Leigh Vosseller EVP & CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
406
+2.09%
|
-
|
May 28
2024
|
Susan Morrison EVP & Chief Admin. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-0.53%
|
$5,967
$51.73 P/Share
|
May 28
2024
|
Susan Morrison EVP & Chief Admin. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
406
+1.82%
|
-
|
May 28
2024
|
Elizabeth Anne Gasser EVP, Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
134
-1.13%
|
$6,834
$51.73 P/Share
|
May 28
2024
|
Elizabeth Anne Gasser EVP, Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
373
+3.04%
|
-
|
May 24
2024
|
Kim D Blickenstaff Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,434
+19.9%
|
$226,134
$51.73 P/Share
|
May 24
2024
|
Dick Allen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,434
+15.38%
|
$226,134
$51.73 P/Share
|
May 24
2024
|
Rebecca B Robertson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,434
+32.06%
|
$226,134
$51.73 P/Share
|
May 24
2024
|
Rajwant Sodhi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,434
+28.48%
|
$226,134
$51.73 P/Share
|
May 24
2024
|
Joao Paulo Falcao Malagueira Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,065
+41.15%
|
$207,315
$51.73 P/Share
|
May 24
2024
|
Kathleen Mc Groddy Goetz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,434
+24.77%
|
$226,134
$51.73 P/Share
|
May 24
2024
|
Christopher J Twomey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,434
+28.2%
|
$226,134
$51.73 P/Share
|
May 24
2024
|
Peyton R Howell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,434
+20.99%
|
$226,134
$51.73 P/Share
|
May 24
2024
|
Myoungil Cha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,065
+41.15%
|
$207,315
$51.73 P/Share
|
May 15
2024
|
John F Sheridan PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,610
-7.13%
|
$498,670
$47.37 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 152K shares |
---|---|
Grant, award, or other acquisition | 7.62K shares |
Open market or private purchase | 14.1K shares |
Payment of exercise price or tax liability | 39.7K shares |
---|